Assembly Biosciences Appoints Gina Consylman to Board of Directors

Rhea-AI Summary

Assembly Biosciences (Nasdaq: ASMB) announced the appointment of Gina Consylman to its board of directors, effective October 20, 2020. Ms. Consylman brings over 25 years of experience in finance and accounting, currently serving as CFO at Ironwood Pharmaceuticals. Her extensive background includes roles at global biotech firms like Biogen and Ernst & Young LLP. With a solid foundation in finance and corporate strategy, her addition aims to strengthen Assembly's leadership team as it develops therapeutics targeting hepatitis B virus and microbiome-related diseases.

Positive

• Gina Consylman's vast experience in finance and corporate strategy could enhance board effectiveness.
• Her leadership at Ironwood Pharmaceuticals suggests strong financial acumen beneficial for ASMB.

Negative

• Potential concerns about continuity and experience gaps if the board does not adapt quickly to her input.

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors. Ms. Consylman will also serve as a member of Assembly’s Audit Committee.

“Gina is an outstanding and complementary addition to Assembly’s board with extensive senior leadership experience across the full spectrum of finance, tax, and strategy,” said William Ringo, chairman of the board at Assembly Biosciences. “From her work at Ironwood Pharmaceuticals to her many years of experience at global biotechnology companies like Biogen, we are confident that Gina will make solid contributions to our success. We are pleased to welcome her to our board.”

Gina Consylman is a 25-year veteran in the field of accounting, finance, and tax. Currently, Ms. Consylman is senior vice president and chief financial officer at Ironwood Pharmaceuticals, a publicly traded healthcare company, where she leads finance, accounting, tax, investor relations, communications, and corporate strategy and development. Ms. Consylman began her career at Ernst & Young LLP and served in financial leadership roles at a number of healthcare and technology companies. Ms. Consylman earned a bachelor’s degree in accounting from Johnson & Wales University, a master’s degree in taxation from Bentley University, and is a Certified Public Accountant. 

“I am inspired by Assembly Biosciences’ team and its commitment to the pursuit of life-changing therapeutics,” said Ms. Consylman. “The company’s achievements to date are indicative of both the strength of the management team and the foundation of innovative and promising science. I look forward to providing my insight and perspectives to help guide their continued advancement in these important disease areas.”

About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Investor Contact
Assembly Biosciences, Inc.
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
lglaser@assemblybio.com

Media Contact
Sam Brown Inc.
Audra Friis
(917) 519-9577
ASMBMedia@sambrown.com

FAQ

Who is Gina Consylman and what role will she play at Assembly Biosciences?

Gina Consylman is appointed to the board of directors and will serve on the Audit Committee, bringing extensive experience in finance.

What experience does Gina Consylman bring to Assembly Biosciences?

She has over 25 years of leadership experience in finance, previously holding senior positions at Ironwood Pharmaceuticals and Biogen.

When was Gina Consylman appointed to Assembly Biosciences' board?

She was appointed on October 20, 2020.

What is the significance of Gina Consylman's appointment for ASMB shareholders?

Her financial expertise may strengthen the company's strategic direction and operational effectiveness, potentially impacting shareholder value positively.